Genentech, Inc. Gets FDA Priority Review for Fenebrutinib in RMS and PPMS

Genentech said the FDA accepted its NDA under priority review for fenebrutinib, a BTK inhibitor for relapsing and primary progressive multiple sclerosis, supported by three Phase III studies.Material DetailsContext by AI AnalystThis is a late-stage regulatory milestone following positive Phase III…